HSV-1716 is under clinical development by Sorrento Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect HSV-1716’s likelihood of approval (LoA) and phase transition for Ewing Sarcoma took place on 28 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 28 May 2021 increased HSV-1716’s Phase Transition Success Rate (PTSR) for Neuroblastoma, increased PTSR for Osteosarcoma, and increased PTSR for Rhabdomyosarcoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their HSV-1716 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

HSV-1716 overview

Seprehvir (HSV-1716) is under development for the treatment of solid tumors including prostate cancer, gastric cancer, neuroblastoma, breast cancer, rhabdomyosarcoma, CNS tumors, Ewing sarcoma, para-spinal malignant peripheral nerve sheath tumor, osteosarcoma, clival chordoma and multiple myeloma,. The drug candidate is administered intratumourally, intravenously and Intrapleurally. The therapeutic candidate is based on viral engineering system named SEPREHVEC and SUPREHVIR.

It was also under development for the treatment of hepatocellular carcinoma, and high grade glioma in pediatrics, head and neck cancer squamous cell carcinoma, metastatic malignant melanoma, high grade glioma and malignant pleural mesothelioma.

Sorrento Therapeutics overview

Sorrento Therapeutics (Sorrento) is a biopharmaceutical company that focuses on developing therapeutics for the treatment of cancer, osteoarthritis and autoimmune diseases. The company’s immunotherapy pipeline portfolio consists of a CD38 CAR-T, CD38 ADC, CD38 DAR-T and Sephrehvir for the treatment of cancer. Sorrento is also investigating COVID19 programs which include Coviguard, Covidrops and Covishield, among others for the treatment of COVID-19. Its marketed products include ZTlido, a lidocaine topical system for the treatment of postherpetic neuralgia (PHN). The company works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. Sorrento is headquartered in San Diego, California, the US.

Quick View HSV-1716 LOA Data

Report Segments
  • Innovator
Drug Name
  • HSV-1716
Administration Pathway
  • Intrapleural
  • Intratumor
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.